Trial Title:
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
NCT ID:
NCT06355843
Condition:
Prostate Cancer
Pet-ct
Conditions: Official terms:
Prostatic Neoplasms
Gallium 68 PSMA-11
Conditions: Keywords:
PSMA
PET/MRI
Prostate Cancer
Study type:
Interventional
Study phase:
N/A
Overall status:
Suspended
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
68Ga-PSMA
Description:
PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein
in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in
prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high
levels in 95% of prostate cancer patients and is upregulated in castration-resistant
prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased
after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA
small molecule inhibitors can be specifically combined with prostate cancer cells, and it
is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT
and PET/MR visualisation.
With the popularity of integrated PET/MR imaging, combining the higher resolution and
morphological performance of MR imaging with the N-staging and M-staging of PET, the
specificity of primary prostate cancer diagnosis can be greatly improved.
Arm group label:
68Ga-FAPI PET/MRI scan
Summary:
The goal of this study type: observational study (prospective study) is to study prostate
cancer occurrence and recurrence, to specifically identify and localize tumor foci at the
molecular level at an early stage, to evaluate the prognosis of patients, and to
accurately stage not only intermediate- and high-risk prostate cancer patients with a
primary diagnosis, but also detect recurrent foci in patients with biochemical
recurrence, to restage those who have developed metastases, to assess tumor load, and to
ultimately assist in determining the personalized treatment plans. The main question it
aims to answer is whether 68Ga-PSMA PET/CT (PET/MR) examination is beneficial for
assessing the
- Accurate staging of patients with intermediate- and high-risk prostate cancer at
first diagnosis;
- Detecting recurrent lesions in patients with recurrent tumors for re-staging;
- Assessment of tumor load;
- Assessment of patient prognosis. Participants will sign an informed consent form,
undergo 68Ga-PSMA PET/CT (PET/MR) before surgery or biopsy, and have regular
follow-up after obtaining pathological results of surgical resection or puncture
biopsy, 6 weeks after surgery or biopsy, and then every 3 months; the follow-up will
include: blood PSA, whole-body bone imaging, etc.
Detailed description:
1. Title of research programme Clinical application of integrated PET/MR and PET/CT in
the diagnosis and treatment of prostate cancer
2. Research background Prostate cancer is the most common malignant tumor of the
urinary system. Current diagnostic tools for prostate cancer include serum
prostate-specific antigen (PSA) test, transrectal prostate aspiration biopsy, etc.
However, these tools are often invasive. When a patient's PSA rises again after
radical prostatectomy for prostate cancer, conventional CT, MRI, and bone
scintigraphy do not have a high detection rate (11%); Although multiparametric
magnetic resonance imaging (mpMRI) is of undisputed importance in the T-staging of
tumors, it has limited diagnostic accuracy when applied alone and is less sensitive
in the diagnosis of local lymph node metastases. Currently, PET/CT has been
gradually applied to different types and stages of prostate cancer. With the
popularity of integrated PET/MR imaging, combining the higher resolution and
morphological performance of MR imaging with the N-staging and M-staging of PET, the
specificity of primary prostate cancer diagnosis can be greatly improved.
Currently, the commonly used targeted tracers for PET examination of prostate cancer
include 18F-fluorodeoxyglucose (18F-FDG), and 18F-/11C-acetate, etc., but their
imaging effects are not up to the ideal level. PSMA is located in prostate
epithelial cells and is converted to a membrane-bound protein in prostate cancer,
and PSMA expression is approximately 100 to 1000 times higher in prostate cancer
tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95%
of prostate cancer patients and is upregulated in castration-resistant prostate
cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased
after androgen deprivation therapy (ADT). The use of 68Ga-labelled PSMA small
molecule inhibitors can be specifically combined with prostate cancer cells, and it
is important for the diagnosis of prostate cancer and its metastatic foci through
PET/CT and PET/MR visualization. 68Ga-PSMA 617 was first applied to prostate cancer
patients in 2015, Afshar-Oromieh et al. conducted the first evaluation of the human
biological distribution, radiation dose of this contrast agent and found that there
was uptake in the kidney and salivary glands, and the detection rate of prostate
cancer lesions was 73.7% (14/19). The best imaging results were obtained 2-3 h after
injection, with an average radiation dose of about 0.021 mSv/mbq.
3. Research purpose This study is expected to be used for prostate cancer occurrence
and recurrence, early specific identification and localization of tumor foci at the
molecular level, and evaluation of patient prognosis. Not only can it accurately
stage first-time intermediate- and high-risk prostate cancer patients, but it can
also detect recurrent lesions in biochemically recurrent patients. Those who develop
metastases are restaged to assess tumor load and ultimately assist in determining a
personalized treatment plan.
4. Type of study design, method of randomization and level of blinding Type of study
design: observational study (prospective study)
5. Diagnostic criteria for prostate cancer Confirmed by prostate puncture biopsy or
surgical pathological histology; Endocrine therapy has shown significant efficacy.
6. Inclusion criteria for participants
- 18 years ≤ 75 years of age;
- Patients with clinical suspicion of prostate cancer;
- No recent invasive tests or treatments were performed;
- Blood count: leukocytes>4×109/L, neutrophils>2×109/L, haemoglobin>90g/L,
platelets>100×109/L;
- Cardiac function: left ventricular ejection fraction >50%;
- Pulmonary function tests: FEV1 ≥1.2L, FEV1% ≥50% and DLCO ≥50%;
- Liver function: total bilirubin <1.5 times upper limit of normal (ULN); AST and
ALT <1.5 times ULN;
- Renal function: serum creatinine ≤ 1.5 times ULN, or glomerular filtration rate
> 60 ml/min;
- Participants agreed to participate in this clinical trial and signed an
informed consent form;
- Good compliance and commitment to follow the study procedures and to cooperate
in the implementation of the full study;
- No birth plans for six months.
7. Exclusion Criteria for Participants
- Those with severe psychiatric symptoms, or those who are too confused to
cooperate with the examination;
- Those with poor compliance.
8. Calculation of the number of cases required to achieve the desired aim of the study
based on statistical principles This was an exploratory observational study and the
sample size was not calculated based on statistical assumptions, and the sample size
was initially determined to be 50 cases.
9. Criteria for discontinuing clinical studies, provisions for ending clinical studies
(1)Significant errors in the clinical research protocol or serious deviations in the
implementation of the protocol that make it difficult to assess the utility of the
study; (2)The drug regulatory authority, government department or ethics committee
asked to suspend or end the study; (3)Circumstances in which other researchers do
not consider it appropriate to continue the study or find it difficult to do so.
10. Subject screening numbers, subject numbers, and case report forms are maintained
Participant Screening Number: a 1-sequential number, e.g., 1-1 for the first
participant; participant Number: a sequential number, e.g., 001 for the first
participant; Case report form retention: information is entered into the CRF form by
the project leader or other authorized investigator, and only medically qualified
investigators are allowed to complete the original clinical assessment/safety data.
Any changes made to the CRF form by the project leader or other authorized
researchers after the original data has been entered need to be documented. Any
modification of data that has been endorsed will require the name of the researcher
or other authorized researcher who made the modification, the date of the
modification, and the reason for the modification (if the change is minor).
11. Documentation of adverse events and methods of reporting serious adverse events,
management measures, modalities, timing and regression of follow-up visits.
11.1 Adverse events Adverse Event (AE) is an unfavorable medical event that occurs
during a clinical trial. Clinical trial Any adverse event that occurs during the
implementation should be faithfully recorded and analyzed for reasons. Both
anticipated and unanticipated adverse events should be be recorded and reported
truthfully. Adverse events should be included as outcome variables in the
statistical analysis of clinical trials.
11.2 Serious adverse event A serious Adverse Event (SAE) is a clinical trial event
that results in death or serious deterioration of health, including fatal illness or
injury, permanent defects in body structure or function, hospitalization or
prolonged hospitalization, or the need for medical or surgical intervention to avoid
permanent defects in body structure or function. Events that result in fetal
distress, fetal death, or congenital anomalies or congenital defects.
11.3 Reporting procedures 11.3.1 Reporting time frames In the event of AE or SAE in
this clinical trial, the investigator shall immediately take appropriate therapeutic
measures for the participant, notify the principal investigator, and report in
writing to the appropriate authorities within 24 hours once SAE has been determined.
11.3.2 Reporting Sector The office of the clinical trial organization to which it
belongs, the sponsor, our Ethics Committee, as well as the drug supervision and
management department of the province, autonomous region, and municipality directly
under the central government where the clinical trial organization is located, and
the competent department of health and wellness.
11.3.3 Reporting methods If an SAE occurs, the investigator completes the Adverse
Event Record Form and files the original Adverse Event Record Form in the
investigator's file folder.
11.3.4 Processing and recording When an SAE or suspected SAE occurs, the
investigator immediately stops the trial and takes appropriate therapeutic measures,
notifies the principal investigator and the sponsor; the principal investigator
makes a judgment about the relevance of the SAE to the trial and records the
occurrence, development, and treatment of the SAE in as much detail as possible on
the Adverse Event Record Form, which is documented on the Case Report Form, signed
and dated.
11.3.5 follow-up If SAE is determined, the event must be followed until it appears
to improve, stabilizes, or, in the judgment of the principal investigator, does not
require follow-up.
12. Statistical analysis plan, definition, and selection of data sets for statistical
analysis 12.1 General approach SPSS software was used for statistical analysis of
data. If the data were normally distributed, they were expressed as mean ± standard
deviation and compared using a two-sample t-test and one-way ANOVA. If the data were
not normally distributed, they were expressed as M(P5, P95) and compared using the
Mann-Whitneyu and Kruskal-WallisH rank sum tests. P<0.05 is considered a
statistically significant difference.
12.2 Analysis of primary and secondary study endpoints Survival analysis was
performed using the Kaplan-Meier method to plot survival curves, and the log-rank
test was used to compare survival differences between groups.
13. Data management and confidentiality of information 13.1 Data entry and modification
Data entry and modification will be done by the Department of Nuclear Medicine, and
data collection will be performed by clinical researchers under the supervision of
the person in charge, who will be responsible for the accuracy, completeness, and
timeliness of the reported data. All data should be clear to ensure accurate
interpretation and to guarantee its traceability. Clinical data will be maintained
in a database, which should be password-protected, and a logical proofreading
process should be in place when the database is created.
The Data Manager is responsible for reviewing and managing the entered data. In case
of doubt about the existence of data, the data manager will send the appropriate
query to the researcher, who will respond to the query sent by the data manager in a
timely manner, and the data manager will be able to re-question the data if
necessary.
13.2 Confidentiality Program for Research Participant Information Participants'
personal information follows the principle of confidentiality. The investigator will
replace the participants' identifying information with a code name that does not
contain his/her name.
13.3 Confidentiality Program for Research Data
14. Quality control and quality assurance in clinical research 14.1 Conditions of
research units and training of personnel The department in which the research
project is located has the appropriate personnel, equipment and first aid
facilities; All research participants (including doctors, nurses, and others) have
received appropriate training in relation to the research and any information
relevant to the conduct of the research has been passed on to the relevant
personnel; All equipment has a technical inspection certificate from the technical
supervision department indicating that it is in good working order; During the
course of the trial study, the investigators should be relatively fixed, and for the
change of investigators in the middle of the study, they should join the study after
training, and the "Clinical Trial Participant Contact Form" should be changed again.
14.2 Modifications to the pilot program Any modifications to the trial protocol that
would affect the execution of the study, the purpose of the trial, the design of the
trial, the number of patient cases and the flow of the trial, etc., must be
submitted as amendments to the trial protocol, which must be agreed upon by the
investigator and the Ethics Committee before they can be implemented.
15. Research-related ethics Participants are not paid and are responsible for some of
the costs. The study was conducted in accordance with China's Measures for Ethical
Review of Biomedical Research Involving Human Beings and international ethical
guidelines such as the Declaration of Helsinki.
16. Methods of subject recruitment and process of obtaining informed consent Participant
Recruitment Methods: Patients meeting the inclusion/exclusion criteria were referred
by the Department of Nuclear Medicine for inclusion in the clinical study.
Informed Consent Process: Informed consent should be completed before the
participant agrees to participate in the study and should continue throughout the
study. The informed consent form was agreed upon by the Ethics Committee and should
be read and signed by the participants. The researcher will explain the research
process answer questions from participants and inform participants of the possible
risks and their rights. Participants may discuss with a family member or guardian
before agreeing to participate. The investigator must inform participants that
participation in the study is voluntary and that they may withdraw from the study at
any time during the study. A copy of the informed consent form can be provided to
the study participant to keep. The rights and welfare of subjects will be protected
and it is emphasized that the quality of their medical care will not be compromised
by refusal to participate in research.
17. Expected progress and completion dates of clinical studies 2022.4.28-2027.3.31
Screening of eligible participants, who underwent relevant examinations as arranged
by the investigator; 2027.4.1-2027.9.30 Complete the statistical analysis of the
experimental data.
18. Follow-up and medical measures at the end of the study Patients are followed up on a
long-term basis and assistance is provided accordingly.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- 18 years ≤ 75 years of age;
- Patients with clinical suspicion of prostate cancer;
- No recent invasive tests or treatments were performed;
- Blood count: leukocytes>4×109/L, neutrophils>2×109/L, haemoglobin>90g/L,
platelets>100×109/L;
- Cardiac function: left ventricular ejection fraction >50%;
- Pulmonary function tests: FEV1 ≥1.2L, FEV1% ≥50% and DLCO ≥50%;
- Liver function: total bilirubin <1.5 times upper limit of normal (ULN); AST and ALT
<1.5 times ULN;
- Renal function: serum creatinine ≤ 1.5 times ULN, or glomerular filtration rate > 60
ml/min;
- Participants agreed to participate in this clinical trial and signed an informed
consent form;
- Good compliance and commitment to follow the study procedures and to cooperate in
the implementation of the full study;
- No birth plans for six months.
Exclusion Criteria:
- Those with severe psychiatric symptoms, or those who are too confused to cooperate
with the examination;
- Those with poor compliance.
Gender:
Male
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
First affiliated hospital of anhui university
Address:
City:
Hefei
Zip:
230032
Country:
China
Start date:
April 28, 2022
Completion date:
March 31, 2027
Lead sponsor:
Agency:
The First Affiliated Hospital of Anhui Medical University
Agency class:
Other
Collaborator:
Agency:
National Natural Science Foundation of China
Agency class:
Other
Source:
The First Affiliated Hospital of Anhui Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06355843
https://pubmed.ncbi.nlm.nih.gov/29129779/
https://pubmed.ncbi.nlm.nih.gov/15493005/
https://pubmed.ncbi.nlm.nih.gov/1289676/
https://pubmed.ncbi.nlm.nih.gov/21149473/
https://pubmed.ncbi.nlm.nih.gov/18207194/
https://pubmed.ncbi.nlm.nih.gov/24207135/
https://pubmed.ncbi.nlm.nih.gov/26361169/
https://pubmed.ncbi.nlm.nih.gov/26334122/
https://pubmed.ncbi.nlm.nih.gov/18325358/
https://pubmed.ncbi.nlm.nih.gov/28267452/
https://pubmed.ncbi.nlm.nih.gov/27609792/
https://pubmed.ncbi.nlm.nih.gov/29786490/
https://pubmed.ncbi.nlm.nih.gov/26681984/
https://pubmed.ncbi.nlm.nih.gov/25598074/
https://pubmed.ncbi.nlm.nih.gov/23041906/
https://pubmed.ncbi.nlm.nih.gov/22369515/
https://pubmed.ncbi.nlm.nih.gov/26116124/
https://pubmed.ncbi.nlm.nih.gov/25883127/
https://pubmed.ncbi.nlm.nih.gov/24072344/
https://pubmed.ncbi.nlm.nih.gov/26294298/
